Disc Medicine, Inc. Stock News

Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel

The mean of analysts' price targets for Disc Medicine, Inc. (IRON) points to a 38.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am

WATERTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel

WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel

Disc Medicine, Inc. (IRON) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Disc Medicine, Inc. (IRON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions coul

Disc Medicine stock has shown outstanding growth since the company joined the Nasdaq in December last year, gaining nearly 250%. The company released data today from a Phase 2 study of lead candidate

Disc Medicine is a clinical-stage biopharmaceutical company specializing in treating blood disorders. The company's lead therapy, bitopertin, is in phase 2 trials to treat a rare inherited blood disor

Disc Medicine, Inc. (IRON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it

WATERTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel

If you are looking for stocks that are well positioned to maintain their recent uptrend, Disc Medicine, Inc. (IRON) could be a great choice. It is one of the several stocks that passed through our "Re

Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's vers

Gemini Therapeutics, Inc. (GMTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revision